Bio-Techne (NASDAQ: TECH) grants president 8,702 and 14,140 RSUs
Rhea-AI Filing Summary
BIO-TECHNE Corp (TECH) reported that its President - Diag & Spatial Bi, Steven C. Crouse, received equity awards on August 17, 2026. He was granted 8,702 restricted stock units and a separate award of 14,140 restricted stock units, each representing a right to one share of common stock, with multi-year vesting schedules through 2029. Following these awards, he directly holds 10,237 shares of common stock and maintains multiple stock option positions on BIO-TECHNE common stock with exercise prices ranging from $48.61 to $120.46 and expirations between 2028 and 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
18 transactions reported
Mixed
18 txns
Insider
Crouse Steven C.
Role
President - Diag & Spatial Bi
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units F8, F15 | 8,702 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units F8, F16 | 14,140 | $0.00 | $0.00 |
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Stock Option (right to buy) F3 | -- | -- | -- |
| holding | Stock Option (right to buy) F4 | -- | -- | -- |
| holding | Stock Option (right to buy) F5 | -- | -- | -- |
| holding | Stock Option (right to buy) F6 | -- | -- | -- |
| holding | Stock Option (right to buy) F7 | -- | -- | -- |
| holding | Performance Restricted Stock Units F8, F9 | -- | -- | -- |
| holding | Restricted Stock Units F8, F10 | -- | -- | -- |
| holding | Restricted Stock Units F8, F11 | -- | -- | -- |
| holding | Restricted Stock Units F8, F12 | -- | -- | -- |
| holding | Restricted Stock Units F8, F13 | -- | -- | -- |
| holding | Restricted Stock Units F8, F14 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 31,793 shares (Direct);
Stock Option (right to buy) — 111,053 shares (Direct);
Performance Restricted Stock Units — 2,387 shares (Direct);
Common Stock — 10,237 shares (Direct)
Footnotes (16)
- F1. 100% vested.
- F2. Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.
- F3. Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.
- F4. Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.
- F5. Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.
- F6. Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.
- F7. Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.
- F8. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F9. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F10. 794 restricted stock units vest on 5/1/2027.
- F11. 600 restricted stock units vest on each of 6/2/2027 and 6/2/2028.
- F12. 1,869 restricted stock units vest on 8/15/2027.
- F13. 2,177 restricted stock units vest on 8/15/2027, and 2,176 restricted stock units vest on 8/15/2028.
- F14. 245 restricted stock units vest on each of 3/2/2027, 3/2/2028 and 3/2/2029.
- F15. 2,901 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 2,900 restricted stock units vest on 8/17/2029.
- F16. 14,140 restricted stock units vest on 8/17/2029.
Key Figures
RSU grant 1: 8,702 units
RSU grant 2: 14,140 units
Direct common stock holdings: 10,237 shares
+3 more
6 metrics
RSU grant 1
8,702 units
Restricted Stock Units granted to Steven C. Crouse on 2026-08-17
RSU grant 2
14,140 units
Restricted Stock Units granted to Steven C. Crouse on 2026-08-17
Direct common stock holdings
10,237 shares
Common Stock directly owned by Steven C. Crouse after reported transactions
Stock option exercise price
$120.46 per share
Option on 19,032 underlying BIO-TECHNE common shares expiring 2028-08-06
Stock option exercise price
$48.61 per share
Option on 5,434 underlying BIO-TECHNE common shares expiring 2035-06-02
Performance RSUs outstanding
2,387 units
Performance Restricted Stock Units vesting based on goals around 2028-08-15
Key Terms
Restricted Stock Units, Performance Restricted Stock Units, Stock Option (right to buy)
3 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"Vests in full or in part on 8/15/2028 if certain performance goals"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Stock Option (right to buy) financial
"Stock Option (right to buy) with specified exercise prices and expirations"
FAQ
What insider equity awards were reported at BIO-TECHNE Corp (TECH)?
BIO-TECHNE Corp reported that President - Diag & Spatial Bi Steven C. Crouse received two restricted stock unit grants on August 17, 2026. The awards cover 8,702 and 14,140 RSUs, each convertible into one share of BIO-TECHNE common stock subject to future vesting.
How do the new BIO-TECHNE (TECH) RSU grants to Steven C. Crouse vest?
The 8,702 RSU grant vests in tranches: 2,901 units on August 17, 2027 and 2028, and 2,900 units on August 17, 2029. The separate 14,140 RSU grant vests entirely on August 17, 2029, assuming continued eligibility under the plan.
What stock options on BIO-TECHNE (TECH) does Steven C. Crouse have outstanding?
Steven C. Crouse holds several stock option positions on BIO-TECHNE common stock, including options over 19,032 underlying shares at an exercise price of $120.46 expiring August 6, 2028, and options over 24,560 shares at $94.52 expiring August 15, 2029.
Does Steven C. Crouse have performance-based RSUs at BIO-TECHNE (TECH)?
Yes. He holds 2,387 performance restricted stock units, each representing a right to one share of BIO-TECHNE common stock. These units vest in full or in part on August 15, 2028, depending on the achievement of specified performance goals certified by the plan administrator.
AI-generated analysis. How Rhea-AI works. Not financial advice.
